KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Receivables (2016 - 2025)

Historic Receivables for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $2.1 billion.

  • Vertex Pharmaceuticals' Receivables rose 2755.06% to $2.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.1 billion, marking a year-over-year increase of 2755.06%. This contributed to the annual value of $2.1 billion for FY2025, which is 2755.06% up from last year.
  • According to the latest figures from Q4 2025, Vertex Pharmaceuticals' Receivables is $2.1 billion, which was up 2755.06% from $1.9 billion recorded in Q3 2025.
  • Vertex Pharmaceuticals' 5-year Receivables high stood at $2.1 billion for Q4 2025, and its period low was $929.1 million during Q2 2021.
  • For the 5-year period, Vertex Pharmaceuticals' Receivables averaged around $1.5 billion, with its median value being $1.6 billion (2023).
  • Per our database at Business Quant, Vertex Pharmaceuticals' Receivables surged by 4345.49% in 2022 and then skyrocketed by 66.36% in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Receivables (Quarter) stood at $1.1 billion in 2021, then rose by 26.86% to $1.4 billion in 2022, then grew by 8.4% to $1.6 billion in 2023, then increased by 2.94% to $1.6 billion in 2024, then grew by 27.55% to $2.1 billion in 2025.
  • Its last three reported values are $2.1 billion in Q4 2025, $1.9 billion for Q3 2025, and $1.9 billion during Q2 2025.